# Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

> **NCT04636437** · PHASE4 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 147 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Doravirine 100 Mg
- **DRUG:** Integrase strand transfer inhibitors
- **DRUG:** Tenofovir alafenamide/emtricitabine
- **DRUG:** tenofovir disproxil fumarate/emtricitabine

## Key facts

- **NCT ID:** NCT04636437
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-27
- **Primary completion:** 2024-10-18
- **Final completion:** 2024-10-18
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04636437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04636437, "Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04636437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*